Full Text View
Tabular View
Study Results
Related Studies
Lamivudine and Adefovir to Treat Chronic Hepatitis B
This study is ongoing, but not recruiting participants.
Study NCT00023309   Information provided by National Institutes of Health Clinical Center (CC)

First Received on September 3, 2001.   Last Updated on February 21, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HBV (Hepatitis B Virus)
Hepatitis B
Hepatitis
Additional conditions recognized in this trial
Hepatitis A
Hepatitis B, Chronic
Hepatitis, Chronic
More general conditions related to this trial
Digestive System Diseases
DNA Virus Infections
Enterovirus Infections
Hepadnaviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
Lamivudine and adefovir
Adefovir alone
Additional drug interventions recognized in this trial
Adefovir
Adefovir dipivoxil
Lamivudine
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services